Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).

作者
D. Ross Camidge,Rebecca Suk Heist,Gregory A. Masters,Ronald J Scheff,Alexander Starodub,Wells A. Messersmith,Aditya Bardia,Allyson J. Ocean,Leora Horn,Jordan D. Berlin,Pius P. Maliakal,Robert M. Sharkey,Francois E. Wilhelm,David M. Goldenberg,Michael J. Guarino
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:34 (15_suppl): 9011-9011 被引量:6
标识
DOI:10.1200/jco.2016.34.15_suppl.9011
摘要

9011 Background: Sacituzumab govitecan (IMMU-132) is an ADC comprising SN-38, the active metabolite of the topoisomerase inhibitor, irinotecan, conjugated to an anti-Trop-2 humanized mAb. In vitro and in vivopreclinical data show that this ADC is efficacious with a high drug:antibody ratio of 7.6, and capable of delivering up to 136-fold more SN-38 than its parent drug, irinotecan, in a human cancer xenograft. The mAb and ADC are immunotherapeutic in vitro (ADCC). Trop-2 expression is increased in most epithelial cancers (>80%), including NSCLC. Therefore, the efficacy and safety of this new ADC is being examined in mNSCLC patients (pts) with > 1st line therapy. Methods: An expansion cohort from a Phase I/II clinical trial (ClinicalTrials.gov, NCT01631552) is enrolling >1st line mNSCLC pts, administering IMMU-132 on days 1 and 8 of 21-day treatment cycles. Treatment continues based on tolerance or until progression, with safety and response (RECIST 1.1) assessments made weekly and every 8 weeks, respectively. Results: Forty-five mNSCLC pts were enrolled by 11/19/15. Thirty-four are assessable [median age 62.5 yrs, 21 M/13 F, ECOG 0 (N=4)/1 (N=29)/unknown (N=1)], with a median of 3 (range, 1-7) prior lines of chemotherapy. All pts received prior treatment with platinum-based therapy. Pts were given IMMU-132 doses of 8 mg/kg (N =9) or 10 mg/kg (N =25). Tumor responses are shown in the Table. Among adverse events collected so far (n=24), grade >3 drug-related toxicities above 5% incidence are diarrhea (8%) and neutropenia (8%). No patient developed antibodies (by ELISA) to the antibody or drug. Conclusions: Objective responses and good tolerability encourage further study of IMMU-132 in mNSCLC pts with > 1st line therapy. Clinical trial information: NCT01631552.IMMU-132 Dosage Objective Response Rate (PR) , including confirmed and unconfirmed Clinical benefit (PR+ SD > 6 Months) Median Progression-Free Survival (Months) (% maturity) Median Overall Survival (Months) (% maturity) 8 mg/kg (N=9) 37% 50% 4.2 (67%) Not Reached (44%) 10 mg/kg (N=25) 29% 33% 3.8 (68%) Not Reached (8%) Both doses (N=34) 31% 35% 3.9 (68%) Not Reached (18%)

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
AY完成签到 ,获得积分10
1秒前
rrr完成签到,获得积分10
1秒前
李佳琪发布了新的文献求助30
1秒前
2秒前
2秒前
lmz发布了新的文献求助10
2秒前
Hj发布了新的文献求助10
3秒前
3秒前
啦啦啦鑫鑫完成签到,获得积分10
3秒前
3秒前
星辰大海的应助被木子采纳,获得10
3秒前
邵赛雨完成签到,获得积分20
3秒前
Hum6le完成签到,获得积分10
4秒前
4秒前
潇洒的辣条完成签到,获得积分10
4秒前
甜美早晨完成签到,获得积分10
5秒前
萨克斯完成签到,获得积分10
5秒前
华仔的应助被lulu采纳,获得10
5秒前
YYQX完成签到,获得积分10
5秒前
狂野的寄松完成签到,获得积分10
5秒前
lx完成签到,获得积分10
5秒前
张思梦发布了新的文献求助10
5秒前
勇敢的胡辣汤完成签到,获得积分20
5秒前
zly完成签到 ,获得积分10
5秒前
Akim的应助被仁爱的沁采纳,获得10
5秒前
liyifei完成签到 ,获得积分10
5秒前
5秒前
yyyyy发布了新的文献求助10
5秒前
丘比特的应助被吕昀翰采纳,获得10
6秒前
6秒前
7秒前
为什么不可用完成签到,获得积分10
7秒前
迷你的怀绿完成签到,获得积分10
7秒前
ww完成签到,获得积分10
8秒前
8秒前
打工人发布了新的文献求助10
8秒前
宋呵呵完成签到,获得积分10
8秒前
132456789完成签到,获得积分20
8秒前
嗯哼完成签到,获得积分10
8秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159929
求助须知:如何正确求助?哪些是违规求助? 9555266
关于积分的说明 21726335
捐赠科研通 7749807
什么是DOI,文献DOI怎么找? 3427310
关于科研通互助平台的介绍 2552391
邀请新用户注册赠送积分活动 2471654